Fig. 1

PRC1 is an independent adverse prognostic factor in WT. (A) Volcano map of DEGs between normal and tumor samples in the TARGET-WT database (|log₂FC| ≥ 2, FDR < 0.05). (B) The Venn diagram was obtained by taking the intersection of 200 EMT-related genes, 84 DEEGs, and 487 DEGs up-regulated in the WT group. (C) The PRC1 mRNA expression by boxplot in WT from TARGET (N = 6; T = 126). (D) K–M survival analysis of PRC1 in WT from TARGET. (E) ROC curves and 1-, 3-, and 5-year AUCs of PRC1 in WT from TARGET. (F) Associations between PRC1 mRNA expression and clinical stage in WT from TARGET. (G) Multivariate Cox hazard regression analysis of three clinical variables (gender, stage, PRC1) in in WT from TARGET. (H) Nomogram based on three clinical variables (gender, stage, PRC1) in WT from TARGET.